Literature DB >> 11263519

The management of anti-tuberculosis drug-induced hepatotoxicity.

K Tahaoğlu1, G Ataç, T Sevim, T Tärün, O Yazicioğlu, G Horzum, I Gemci, A Ongel, N Kapakli, E Aksoy.   

Abstract

SETTING: A tuberculosis ward in a chest disease teaching hospital.
OBJECTIVE: To compare the efficacy of two different retreatment protocols on hepatotoxicity recurrence in tuberculosis treatment.
DESIGN: In a prospective, randomised study, 45 patients with new tuberculosis developed hepatotoxicity after anti-tuberculosis treatment. Patients in Group I (n = 20) were retreated with a drug regimen consisting of isoniazid, rifampicin, ethambutol and streptomycin administered by gradually increasing the number and dosage of the drugs. Patients in Group II (n = 25) were retreated with the same regimen (isoniazid, rifampicin, pyrazinamide and ethambutol) in the same dosages throughout.
RESULTS: Hepatotoxicity recurred in respectively zero and six (24%) patients in Groups I and II (P = 0.021). Of the six patients with recurrence of hepatitis, one could not be followed up. The other five received the same retreatment protocol as Group I. By the end of retreatment, all patients were cured.
CONCLUSION: The recurrence rate of hepatotoxicity in the retreatment of tuberculosis is higher in the reintroduction of a full-dose regimen including pyrazinamide, which causes more hepatotoxicity than gradual reintroduction of a regimen without pyrazinamide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11263519

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  20 in total

1.  Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.

Authors:  Tarjinder Sahota; Oscar Della Pasqua
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

2.  Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India.

Authors:  Arunava Saha; Margaret Shanthi F X; Blessed Winston A; Saibal Das; Aniket Kumar; Joy S Michael; T Balamugesh
Journal:  J Prim Care Community Health       Date:  2016-04-07

3.  Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors:  Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

Review 4.  Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.

Authors:  Vidyasagar Ramappa; Guruprasad P Aithal
Journal:  J Clin Exp Hepatol       Date:  2012-12-20

Review 5.  An Update on Drug-induced Liver Injury.

Authors:  Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

6.  Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus.

Authors:  Lei Pan; Zhan-Sheng Jia; Lin Chen; En-Qing Fu; Guang-Yu Li
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

Review 7.  Mechanisms of drug-induced liver injury: from bedside to bench.

Authors:  Shannan Tujios; Robert J Fontana
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

8.  A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.

Authors:  Hoda A Makhlouf; Ahmed Helmy; Ehab Fawzy; Madiha El-Attar; Hebat Alla G Rashed
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

9.  Anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra pulmonary tuberculosis.

Authors:  Zaher Al-Salmi
Journal:  Saudi Pharm J       Date:  2011-09-23       Impact factor: 4.330

Review 10.  Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.

Authors:  Juliana Hey-Hadavi; Daniel Seekins; Melissa Palmer; Denise Coffey; John Caminis; Sandzhar Abdullaev; Meenal Patwardhan; Haifa Tyler; Ritu Raheja; Ann Marie Stanley; Liliam Pineda-Salgado; David L Bourdet; Raul J Andrade; Paul H Hayashi; Lara Dimick-Santos; Don C Rockey; Alvin Estilo
Journal:  Drug Saf       Date:  2021-03-16       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.